These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 2089048)

  • 21. Estimation of population pharmacokinetic parameters of free-phenytoin in adult epileptic patients.
    Deleu D; Aarons L; Ahmed IA
    Arch Med Res; 2005; 36(1):49-53. PubMed ID: 15777995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive performance of pharmacokinetic methods for phenytoin dosing: a multi-center evaluation in 282 patients with epilepsy.
    Zaccara G; Messori A; Muscas GC; Albani F; Baruzzi A; Bianchi A; Riva R; Valenza T; Zagnoni P; Zolo P
    Epilepsy Res; 1989; 3(3):253-61. PubMed ID: 2659322
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apparent Michaelis-Menten kinetic parameters of phenytoin in pediatric patients.
    Chiba K; Ishizaki T; Miura H; Minagawa K
    Pediatr Pharmacol (New York); 1980; 1(2):171-80. PubMed ID: 7346739
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Non-steady state population kinetics of intravenous phenytoin.
    Frame B; Beal SL
    Ther Drug Monit; 1998 Aug; 20(4):408-16. PubMed ID: 9712466
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phenytoin kinetics in Japanese adult epileptics: phenotype of phenytoin slow metabolizers.
    Watanabe M; Iwahashi K; Kugoh T; Suwaki H
    Clin Neuropharmacol; 1997 Aug; 20(4):346-51. PubMed ID: 9260732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Blood levels of phenytoin. Pharmacokinetics and individualization of dosages in controlled children with crises and with persistence of crises].
    García-Márquez F; Rodríguez-Blancas MC; Juárez-Olguín H; Díaz-López B; Ruiz-Chávez J
    Bol Med Hosp Infant Mex; 1990 Oct; 47(10):682-8. PubMed ID: 2278644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Population pharmacokinetics of phenytoin in pediatric patients].
    Wang J; Liang WQ; Wu JJ
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2003 Feb; 32(1):46-50. PubMed ID: 12640710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of aging on serum phenytoin concentrations: a pharmacokinetic analysis based on therapeutic drug monitoring data.
    Battino D; Croci D; Mamoli D; Messina S; Perucca E
    Epilepsy Res; 2004; 59(2-3):155-65. PubMed ID: 15246117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of phenytoin in critically ill trauma patients.
    Boucher BA; Rodman JH; Fabian TC; Cupit GC; Ludden TM; West ME; Ray MW
    Clin Pharm; 1987 Nov; 6(11):881-7. PubMed ID: 3677565
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Validation of population pharmacokinetic parameters of phenytoin using the parallel Michaelis-Menten and first-order elimination model.
    Valodia PN; Seymour MA; McFadyen ML; Miller R; Folb PI
    Ther Drug Monit; 2000 Jun; 22(3):313-9. PubMed ID: 10850399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population pharmacokinetics of phenytoin in South African black patients.
    Miller R; Rheeders M; Klein C; Suchet I
    S Afr Med J; 1987 Aug; 72(3):188-90. PubMed ID: 3603312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phenytoin dosing in obese patients: two case reports.
    de Oca GM; Gums JG; Robinson JD
    Drug Intell Clin Pharm; 1988 Sep; 22(9):708-10. PubMed ID: 3215115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of pharmacokinetic interaction between zileuton and phenytoin in humans.
    Samara E; Cavanaugh JH; Mukherjee D; Granneman GR
    Clin Pharmacokinet; 1995; 29 Suppl 2():84-91. PubMed ID: 8620675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age and phenytoin kinetics in adult epileptics.
    Bauer LA; Blouin RA
    Clin Pharmacol Ther; 1982 Mar; 31(3):301-4. PubMed ID: 7060313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developing a nomogram for dose individualization of phenytoin in Asian pediatric patients derived from population pharmacokinetic modeling of saturable pharmacokinetic profiles of the drug.
    Lee FX; Kong ST; Chan DW; Chan E; Tan WW; Ho PC
    Ther Drug Monit; 2013 Feb; 35(1):54-62. PubMed ID: 23222687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of a clinically significant effect of zonisamide on phenytoin steady-state pharmacokinetics in patients with epilepsy.
    Levy RH; Ragueneau-Majlessi I; Garnett WR; Schmerler M; Rosenfeld W; Shah J; Pan WJ
    J Clin Pharmacol; 2004 Nov; 44(11):1230-4. PubMed ID: 15496640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Utilization of Km for phenytoin dosage after folate addition to patient regimen.
    Berg MJ; Ebert BE; Rivey MP; Schottelius DD
    Ther Drug Monit; 1987 Sep; 9(3):304-5. PubMed ID: 3672574
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of phenytoin in children with acute neurotrauma.
    O'Mara NB; Jones PR; Anglin DL; Cox S; Nahata MC
    Crit Care Med; 1995 Aug; 23(8):1418-24. PubMed ID: 7634814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Covariance analysis of laboratory variance in steady-state serum phenytoin concentrations.
    Costeff H; Groswasser Z; Soroker N; van Belle G
    Clin Pharmacokinet; 1991 Apr; 20(4):331-5. PubMed ID: 2036750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Benefits of a clinical pharmacokinetic service in optimising phenytoin use in the western Cape.
    Valodia P; Seymour MA; Kies BM; Folb PI
    S Afr Med J; 1998 Jul; 88(7):873-5. PubMed ID: 9698715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.